MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting
MeiraGTx will present four posters at the ESGCT 2026 Annual Congress in Hamburg and the NEALS Annual Meeting in Clearwater, FL, both running October 27-30. The posters cover a commercial potency assay for rAAV-AQP1 in xerostomia, an improved AAV characterization method, pre-clinical AAV-NRF2 data in dry AMD models, and development of AAV-hUPF1 and AAV-hCNTFRa as potential ALS therapeutics.
Key figures
- Poster count
- 4
- Preclinical aav upf1 transduction
- approximately 36%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.